Glycine modulators in schizophrenia.
N-methyl-D-aspartate (NMDA) receptor dysfunction may play a key role in the pathophysiology of schizophrenia. Recent studies have investigated the ability of NMDA/glycine-site modulators to ameliorate persistent negative and cognitive symptoms. Several full or partial glycine-site agonists, including glycine, D-serine and D-cycloserine, have shown effectiveness in small-scale clinical trials. Glycine levels in brain are regulated by GLYT1-type glycine transporters. Recently developed glycine transport inhibitors (GTI) have preclinical behavioral effects similar to those of glycine or D-serine, and may represent a 'next generation' approach to the treatment of the persistent negative and cognitive symptoms of schizophrenia.